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ABSTRACT
Stiff person syndrome (SPS) is a rare neurological disorder characterized by progressive muscle stiffness and rigidity, 
mostly involving axial muscles, resulting in functional disability. It is associated with elevated anti- Glutamic acid decar-
boxylase (GAD) antibody levels. Electromyography findings are often diagnostic. We present a case of a 48 years old 
male, who presented with progressive stiffness and rigidity of axial muscles and limbs. His EMG was consistent with 
SPS. Anti GAD antibodies were markedly elevated. He was treated with rituximab and has improved significantly. SPS 
is a difficult diagnosis, usually under diagnosed due to lack of awareness among medical community. There is a dire 
need to further study the disease and invent better treatment options for patients suffering from SPS. 
C A S E  R E P O R T
CASE REPORT
A 48 year old male, known case of Type l Diabetes Mellitus 
and depression, presented to Neurology Outpatient depart-
ment with complaints of progressive pain and stiffness of 
neck, shoulder and abdominal muscles for the past six 
months. The pain and spasm aggravated with stress and 
movement and was temporarily relieved on taking Non 
steroidal anti-inflammatory drugs and muscle relaxants. 
Initially he did not have any disability and despite stiffness 
he was able to carry out his daily life activity. However, the 
stiffness worsened over time, resulting in difficulty in walking 
and performing daily tasks. Physical examination revealed 
stiffness over muscles of neck, shoulder and abdominal 
regions. He had a robot like gait. Rest of the neurological 
examination, including cranial nerves, motor and sensory 
examination, was unremarkable. Based on the history and 
physical examination he appeared to be suffering from stiff 
person syndrome. The pertinent baseline investigations 
were normal (Table 1). 
Table 1: Pertinent baseline investigations
Anti-GAD antibodies were sent which were found to be 
markedly elevated to a level of > 2000IU/mL. To further 
confirm our diagnosis, Electromyography (EMG) was 
done, which showed continuous motor activity in agonist 
and antagonists muscles, subsiding on the administra-
tion of Intravenous diazepam 5 mg (Figure 1).
  
         
Figure1a
Figure 1: EMG showing a) continuous motor activity 
which b) subsided on giving 5 mg IV diazepam.
The patient was treated with Diazepam 2.5mg PO qHS 
and Baclofen 5mg three times daily. On a two week 
follow up visit, the patient showed improvement in pain, 
stiffness and functional status. A Rheumatology consult 
Laboratory Investigation  Results
CRP    2.35 U/L
ESR    2 mm 1st hr
Calcium    9.4 mg/dL
25 Hydroxy Vitamin D  36.2 ng/mL
TSH    2.18 micro IU/L
CPK    199 U/L
Aldolase    7.0  U/L
X-Ray Lumbo-sacral spine  Unremarkable
MRI brain with contrast  Normal 
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was sought regarding the disease modifying treatment 
options, and Rituximab infusion was advised after 
screening for Hepatitis B and C.
Figure1b
He was given a total of three doses of Rituximab infusion 
500mg in 500ml of normal saline over 2 to 3 hours, 
each one week apart. He was pre-medicated with  Injec-
tion Methylprednisolone 100mg diluted  in 500mL of 
Normal saline given intravenously along with two tablets 
of acetaminophen 500mg per orally and Injection chlor-
phenamine 10mg Intravenously. Complete blood count, 
Liver function tests, Blood urea nitrogen and creatinine 
were checked after the administration of first and third 
dose and were normal. Anti GAD antibodies will be 
re-checked after two months.
DISCUSSION
Stiff person syndrome (SPS) is a rare neurological disor-
der characterized by fluctuating muscle rigidity of trunk 
and limbs resulting in abnormal postures (1). Muscle 
rigidity and episodic spasms result in functional disability 
of the patients. This rare neurological disorder was first 
described by Moersch and Woltman in 1956 (2). A Dala-
kas criterion, as given below (Table 2) is the most widely 
used scale for establishing the diagnosis of SPS (3). 
Table 2. Dalakas Criteria
The exact cause of the disease is yet unknown. Most 
patients with classical SPS have antibody against 
Glutamic acid decarboxylase (GAD), an enzyme that 
plays a vital role in the regulation of an important inhibi-
tory neurotransmitter of Central nervous system, gamma 
amino butyric acid (GABA) .Destruction of the GAD 
enzyme results in less availability of GABA neurotransmit-
ter and hence, leads to excessive stimulation of the 
muscles by motor neurons causing muscle stiffness (4). 
SPS is a clinical diagnosis, confirmed using Electromyo-
graphy (EMG). EMG of patients with SPS shows continu-
ous motor activity which can be suppressed by diazepam. 
This is a confirmatory test (5). Anti GAD antibodies are 
also checked in patients suspected for SPS. In approxi-
mately 85% of patients with SPS have high titers of anti 
GAD antibodies (6). There is a strong suspicion of an asso-
ciation between SPS and other autoimmune diseases. 
SPS is more commonly seen in patients with insulin 
dependent diabetes mellitus, thryoiditis, paraneoplastic 
syndromes and epilepsy (7). SPS has no permanent cure. 
However two therapeutic strategies have been tried for 
patients with SPS. First includes the use of GABA 
enhancing medications for symptomatic relief by 
decreasing muscle stiffness. Baclofen and benzodiaz-
epines are most commonly used drugs for this purpose. 
These drugs increase GABA activity and hence alleviate 
muscle stiffness (8).The second approach is to use 
disease modifying agents like rituximab and intravenous 
immunoglobulin to decrease the progression of the 
disease (9). Both treatment approaches along with physi-
cal and occupations therapy should be used in patients 
for ultimate favorable results. The role of steroids and 
plasma exchange is still questionable. New trials are 
being conducted to study the role of rituximab in patients 
with stiff person syndrome. According to the studies 
conducted so far, clinical improvement has been seen in 
patients using rituximab especially in those who did not 
respond well to traditional therapy (10). Further studies are 
needed before it could become an established drug of 
choice for SPS. 
CONCLUSION
SPS is an under diagnosed neurological disorder. This is 
due to lack of awareness of the disease among medical 
community. In order to avoid delay in the treatment and 
improve prognosis, early diagnosis is necessary. A 
multi-disciplinary approach can help in diagnosing and 
managing such patients. 
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